These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20485896)

  • 1. Bone turnover assessment: a good surrogate marker?
    Dreyer P; Vieira JG
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):99-105. PubMed ID: 20485896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring.
    Garnero P
    Mol Diagn Ther; 2008; 12(3):157-70. PubMed ID: 18510379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone turnover: Biology and assessment tools.
    Szulc P
    Best Pract Res Clin Endocrinol Metab; 2018 Oct; 32(5):725-738. PubMed ID: 30449551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical points in strategies for the diagnosis and treatment of osteoporosis.
    Lorenc RS; Misiorowski W; Karczmarewicz E
    Endokrynol Pol; 2009; 60(2):124-33. PubMed ID: 19396756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of the World Health Organization Fracture Risk Assessment Tool to predict need for dual-energy X-ray absorptiometry scanning in postmenopausal women.
    Chao AS; Chen FP; Lin YC; Huang TS; Fan CM; Yu YW
    Taiwan J Obstet Gynecol; 2015 Dec; 54(6):722-5. PubMed ID: 26700992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of dual-energy X-ray absorptiometry, calcaneal quantitative ultrasound, and fracture risk indices (FRAX® and Osteoporosis Risk Assessment Instrument) for the identification of women with distal forearm or hip fractures: A pilot study.
    Esmaeilzadeh S; Cesme F; Oral A; Yaliman A; Sindel D
    Endocr Res; 2016 Aug; 41(3):248-60. PubMed ID: 26864472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?
    Bonnick SL; Shulman L
    Am J Med; 2006 Apr; 119(4 Suppl 1):S25-31. PubMed ID: 16563938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone turnover markers: understanding their value in clinical trials and clinical practice.
    Civitelli R; Armamento-Villareal R; Napoli N
    Osteoporos Int; 2009 Jun; 20(6):843-51. PubMed ID: 19190842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Trabecular Bone Score (TBS) as a Complementary Approach to Dual-energy X-ray Absorptiometry (DXA) for Fracture Risk Assessment in Clinical Practice.
    Shevroja E; Lamy O; Kohlmeier L; Koromani F; Rivadeneira F; Hans D
    J Clin Densitom; 2017; 20(3):334-345. PubMed ID: 28734710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Follow-up of osteoporosis treatment].
    Lespessailles E
    Presse Med; 2006 Oct; 35(10 Pt 2):1565-70. PubMed ID: 17028522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?
    Briot K; Roux C
    Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):951-64. PubMed ID: 16301189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction.
    Miller PD
    Curr Osteoporos Rep; 2005 Sep; 3(3):103-10. PubMed ID: 16131430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is bone mineral density predictive of fracture risk reduction?
    Cefalu CA
    Curr Med Res Opin; 2004 Mar; 20(3):341-9. PubMed ID: 15025843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.
    Rossini M; Zanotti R; Bonadonna P; Artuso A; Caruso B; Schena D; Vecchiato D; Bonifacio M; Viapiana O; Gatti D; Senna G; Riccio A; Passalacqua G; Pizzolo G; Adami S
    Bone; 2011 Oct; 49(4):880-5. PubMed ID: 21782049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The assessment of fracture risk.
    Unnanuntana A; Gladnick BP; Donnelly E; Lane JM
    J Bone Joint Surg Am; 2010 Mar; 92(3):743-53. PubMed ID: 20194335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to predict and treat increased fracture risk in chronic kidney disease.
    West SL; Patel P; Jamal SA
    J Intern Med; 2015 Jul; 278(1):19-28. PubMed ID: 25758353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?
    Seeman E
    Bone; 2007 Sep; 41(3):308-17. PubMed ID: 17644058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.
    Hochberg MC; Greenspan S; Wasnich RD; Miller P; Thompson DE; Ross PD
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1586-92. PubMed ID: 11932287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of bone turnover to bone density and fractures.
    Melton LJ; Khosla S; Atkinson EJ; O'Fallon WM; Riggs BL
    J Bone Miner Res; 1997 Jul; 12(7):1083-91. PubMed ID: 9200008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.